查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球基因載體市場研究報告 - 行業分析、規模、佔有率、成長、趨勢及2023至2030年預測
市場調查報告書
商品編碼
1305196

全球基因載體市場研究報告 - 行業分析、規模、佔有率、成長、趨勢及2023至2030年預測

Global Gene Vector Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日期: | 出版商: Value Market Research | 英文 240 Pages | 商品交期: 最快1-2個工作天內

價格

據預測，到2030年，全球基因載體市場需求將從2022年的993.72百萬美元達到近3160.79百萬美元，2023-2030年的複合年成長率為13.72%。

基因載體是一種用於將遺傳物質轉移到細胞、組織或器官中以改變或替換其遺傳組成的工具。基因載體通常用於基因工程、基因治療和生物技術研究。基因載體有多種類型，包括病毒載體和非病毒載體。病毒載體來源於病毒，可用於將遺傳物質高效地傳遞給細胞。病毒載體的例子包括逆轉錄病毒、腺病毒和慢病毒。另一方面，非病毒載體通常由DNA或RNA製成，效率低於病毒載體。非病毒載體的例子包括質粒、脂質體和奈米顆粒。基因載體應用廣泛，包括基因治療，用於向細胞傳遞健康基因以治療遺傳疾病。基因載體還用於研究基因功能、創建轉基因生物和開發新的生物技術產品。

市場動態：

癌症、囊性纖維化和鐮狀細胞性貧血等遺傳疾病發病率的上升推動了對基因載體的需求。基因載體用於基因治療，這是一種通過向細胞傳遞健康基因來治療遺傳疾病的有效方法。基因治療技術的不斷進步，如開發更安全、更高效的基因載體，推動了基因載體市場的成長。這包括病毒載體的使用，如慢病毒和腺相關病毒，它們具有更好的安全性和有效性。政府、私營公司和研究機構對基因治療研究進行了大量投資。這推動了新型基因療法的開發，並將基因載體作為提供這些療法的關鍵工具。個性化醫療，即根據個人的特定基因組成進行治療，是醫療保健領域日益成長的趨勢。基因載體是提供個性化醫療的重要工具，這也推動了基因載體的應用。患者、醫療服務提供者和監管機構對基因療法的認知和接受程度不斷提高。這推動了基因載體作為基因治療關鍵工具的應用。

研究報告包括波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於在全球範圍內清晰地了解行業結構和評估競爭吸引力。此外，這些工具還對全球基因載體市場的各個細分市場進行了全面評估。基因載體行業的成長和趨勢為本研究提供了整體方法。

市場細分：

基因載體市場報告的這一部分提供了國家和地區層面細分市場的詳細數據，從而幫助戰略家確定各自產品或服務的目標人群以及即將到來的機會。

按載體類型

  • 慢病毒
  • 腺病毒
  • 腺相關病毒（AAV）
  • 質粒DNA
  • 其他載體

按應用分類

  • 基因治療
  • 疫苗學
  • 其他應用

按疾病分類

  • 遺傳性疾病
  • 癌症
  • 傳染病
  • 其他疾病

按最終用戶

  • 科學研究
  • CRO
  • CDMO
  • 其他（製藥、生物技術公司）

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太、拉丁美洲、中東和非洲地區基因載體市場的當前和未來需求。此外，報告還重點分析了所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的綜合概況以及全球競爭格局的深入分析。基因載體市場的主要企業包括Lonza、Merck KGaA、Oxford Biomedica、CGT Catapult、Charles River Laboratories、uniQure NV、FUJIFILM Diosynth Biotechnologies、Spark Therapeutics, Inc.本節包括競爭格局的整體觀點，其中包括各種戰略發展，如關鍵併購、未來能力、合作夥伴關係、財務概況、合作、新產品開發、新產品上市和其他發展。

目 錄

第一章：前言

  • 報告描述
    • 報告目標
    • 目標受眾
    • 獨特銷售主張（USP）和產品
  • 研究範圍
  • 研究方法
    • 市場調研流程
    • 市場調研方法

第二章：執行摘要

  • 市場亮點
  • 全球市場概況

第三章：基因載體-行業分析

  • 簡介- 市場動態
  • 市場驅動因素
  • 市場限制因素
  • 市場機會
  • 行業趨勢
  • 波特五力分析
  • 市場吸引力分析
    • 按載體類型的市場吸引力分析
    • 市場吸引力分析：按應用
    • 按疾病分類的市場吸引力分析
    • 按最終用戶的市場吸引力分析
    • 市場吸引力分析：按地區

第四章：價值鏈分析

  • 價值鏈分析
  • 原料分析
    • 原料清單
    • 原料製造商列表
    • 主要原料價格走勢
  • 潛在買家名單
  • 行銷管道
    • 直接行銷
    • 間接行銷
    • 行銷管道發展趨勢

第五章：Covid-19疫情影響分析

第六章：全球基因載體市場分析：按載體類型分類

  • 載體類型概述
  • 歷史和預測數據
  • 載體類型分析
  • 慢病毒
  • 腺病毒
  • 腺相關病毒（AAV）
  • 質粒DNA
  • 其他載體

第七章：全球基因載體市場分析：按應用分類

  • 概述：按應用分類
  • 歷史和預測數據
  • 分析：按應用
  • 基因治療
  • 疫苗學
  • 其他

第八章：全球基因載體市場分析：按疾病分類

  • 疾病概述
  • 歷史和預測數據
  • 疾病分析
  • 遺傳性疾病
  • 癌症
  • 傳染病
  • 其他疾病

第九章：全球基因載體市場分析：按最終用戶分類

  • 終端用戶概述
  • 歷史和預測數據
  • 終端用戶分析
  • 科學研究
  • CRO
  • CDMO
  • 其他（製藥、生物技術公司）

第10章：全球基因載體市場分析：按地域分類

  • 地區前景
  • 地區介紹
  • 北美銷售分析
    • 概述、歷史及預測銷售分析
    • 北美地區銷售分析
    • 北美地區各國銷售分析
    • 美國銷售分析
    • 加拿大銷售分析
    • 墨西哥銷售分析
  • 歐洲銷售分析
    • 概述、歷史和預測銷售分析
    • 歐洲銷售分析
    • 歐洲各國銷售分析
    • 英國銷售分析
    • 法國銷售分析
    • 德國銷售分析
    • 義大利銷售分析
    • 俄羅斯銷售分析
    • 歐洲其他地區銷售分析
  • 亞太地區銷售分析
    • 概述、歷史和預測銷售分析
    • 亞太地區各細分市場銷售分析
    • 亞太地區各國銷售分析
    • 中國銷售分析
    • 印度銷售分析
    • 日本銷售分析
    • 韓國銷售分析
    • 澳大利亞銷售分析
    • 亞太其他地區銷售分析
  • 拉丁美洲銷售分析
    • 概述、歷史和預測銷售分析
    • 拉丁美洲各細分市場銷售分析
    • 拉丁美洲各國銷售分析
    • 巴西銷售分析
    • 阿根廷銷售分析
    • 秘魯銷售分析
    • 智利銷售分析
    • 拉丁美洲其他地區銷售分析
  • 中東和非洲銷售分析
    • 概述、歷史和預測銷售分析
    • 中東和非洲各細分市場銷售分析
    • 中東和非洲國家銷售分析
    • 沙烏地阿拉伯銷售分析
    • 阿拉伯聯合大公國銷售分析
    • 以色列銷售分析
    • 南非銷售分析
    • 中東及非洲其他地區銷售分析

第十一章：基因載體企業競爭格局

  • 基因載體市場競爭
  • 夥伴關係/合作/協議
  • 合併與收購
  • 新產品上市
  • 其他發展

第十二章：公司概況

  • 頂級公司佔有率分析
  • 市場集中度
  • Lonza
    • 公司概況
    • 公司收入
    • 產品
    • 近期發展
  • Merck KGaA
    • 公司概況
    • 公司收入
    • 產品
    • 近期發展
  • Oxford Biomedica
    • 公司概況
    • 公司收入
    • 產品
    • 近期發展
  • CGT Catapult
    • 公司概況
    • 公司收入
    • 產品
    • 近期發展
  • Charles River Laboratories
    • 公司概況
    • 公司收入
    • 產品
    • 近期發展
  • uniQure NV
    • 公司概況
    • 公司收入
    • 產品
    • 近期發展
  • FUJIFILM Diosynth Biotechnologies
    • 公司概況
    • 公司收入
    • 產品
    • 近期發展
  • Spark Therapeutics Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 近期發展

*注：在公司概況中，財務細節和近期發展取決於可用性，如果是私營公司，則可能不包括在內。

Product Code: VMR112110627

The global demand for Gene Vector Market is presumed to reach the market size of nearly USD 3160.79 MN by 2030 from USD 993.72 MN in 2022 with a CAGR of 13.72% under the study period 2023 - 2030.

A gene vector is a tool used to transfer genetic material into cells, tissues, or organs in order to alter or replace their genetic makeup. Gene vectors are commonly used in genetic engineering, gene therapy, and biotechnology research. There are several types of gene vectors, including viral and non-viral vectors. Viral vectors are derived from viruses and can be used to deliver genetic material to cells in a highly efficient manner. Examples of viral vectors include retroviruses, adenoviruses, and lentiviruses. Non-viral vectors, on the other hand, are typically made from DNA or RNA and are less efficient than viral vectors. Examples of non-viral vectors include plasmids, liposomes, and nanoparticles. Gene vectors are used in a wide range of applications, including gene therapy, where they are used to deliver healthy genes to cells in order to treat genetic diseases. They are also used in research to study gene function, create transgenic organisms, and develop new biotechnology products.

Market Dynamics:

The rising incidence of genetic disorders, such as cancer, cystic fibrosis, and sickle cell anaemia, is driving the demand for gene vectors. Gene vectors are used in gene therapy, a promising approach for treating genetic disorders by delivering healthy genes to cells. Ongoing advancements in gene therapy technology, such as the development of safer and more efficient gene vectors, are driving the growth of the gene vector market. This includes the use of viral vectors, such as lentiviruses and adeno-associated viruses, which have improved safety and efficacy profiles. There is a significant amount of investment being made in gene therapy research by governments, private companies, and research institutions. This is driving the development of new gene therapies and the use of gene vectors as key tools in their delivery. Personalized medicine, which involves tailoring treatment to an individual's specific genetic makeup, is a growing trend in healthcare. Gene vectors are a critical tool in delivering personalized medicine, which is driving their adoption. There is increasing awareness and acceptance of gene therapy among patients, healthcare providers, and regulatory bodies. This is driving the adoption of gene vectors as a key tool in gene therapy.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of gene vector. The growth and trends of gene vector industry provide a holistic approach to this study.

Market Segmentation:

This section of the gene vector market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Vector Type

  • Lentivirus
  • Adenovirus
  • Adeno-Associated Virus (AAV)
  • Plasmid DNA
  • Others

By Application

  • Gene Therapy
  • Vaccinology
  • Others

By Disease

  • Genetic Disorder
  • Cancer
  • Infectious Disease
  • Others

By End-User

  • Scientific Research
  • CRO
  • CDMO
  • Others (Pharmaceutical, Biotechnology Companies)

Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Gene Vector market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the gene vector market include Lonza, Merck KGaA, Oxford Biomedica, CGT Catapult, Charles River Laboratories, uniQure N.V., FUJIFILM Diosynth Biotechnologies, Spark Therapeutics, Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . GENE VECTOR - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Vector Type
    • 3.7.2 Market Attractiveness Analysis By Application
    • 3.7.3 Market Attractiveness Analysis By Disease
    • 3.7.4 Market Attractiveness Analysis By End-user
    • 3.7.5 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL GENE VECTOR MARKET ANALYSIS BY VECTOR TYPE

  • 6.1 Overview by Vector Type
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Vector Type
  • 6.4 Lentivirus Historic and Forecast Sales by Regions
  • 6.5 Adenovirus Historic and Forecast Sales by Regions
  • 6.6 Adeno-associated Virus (AAV) Historic and Forecast Sales by Regions
  • 6.7 Plasmid DNA Historic and Forecast Sales by Regions
  • 6.8 Others Historic and Forecast Sales by Regions

7 . GLOBAL GENE VECTOR MARKET ANALYSIS BY APPLICATION

  • 7.1 Overview by Application
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Application
  • 7.4 Gene Therapy Historic and Forecast Sales by Regions
  • 7.5 Vaccinology Historic and Forecast Sales by Regions
  • 7.6 Others Historic and Forecast Sales by Regions

8 . GLOBAL GENE VECTOR MARKET ANALYSIS BY DISEASE

  • 8.1 Overview by Disease
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by Disease
  • 8.4 Genetic Disorder Historic and Forecast Sales by Regions
  • 8.5 Cancer Historic and Forecast Sales by Regions
  • 8.6 Infectious Disease Historic and Forecast Sales by Regions
  • 8.7 Others Historic and Forecast Sales by Regions

9 . GLOBAL GENE VECTOR MARKET ANALYSIS BY END-USER

  • 9.1 Overview by End-user
  • 9.2 Historical and Forecast Data
  • 9.3 Analysis by End-user
  • 9.4 Scientific Research Historic and Forecast Sales by Regions
  • 9.5 CRO Historic and Forecast Sales by Regions
  • 9.6 CDMO Historic and Forecast Sales by Regions
  • 9.7 Others (Pharmaceutical, Biotechnology Companies) Historic and Forecast Sales by Regions

10 . GLOBAL GENE VECTOR MARKET ANALYSIS BY GEOGRAPHY

  • 10.1. Regional Outlook
  • 10.2. Introduction
  • 10.3. North America Sales Analysis
    • 10.3.1. Overview, Historic and Forecast Sales Analysis
    • 10.3.2. North America By Segment Sales Analysis
    • 10.3.3. North America By Country Sales Analysis
    • 10.3.4. United State Sales Analysis
    • 10.3.5. Canada Sales Analysis
    • 10.3.6. Mexico Sales Analysis
  • 10.4. Europe Sales Analysis
    • 10.4.1. Overview, Historic and Forecast Sales Analysis
    • 10.4.2. Europe by Segment Sales Analysis
    • 10.4.3. Europe by Country Sales Analysis
    • 10.4.4. United Kingdom Sales Analysis
    • 10.4.5. France Sales Analysis
    • 10.4.6. Germany Sales Analysis
    • 10.4.7. Italy Sales Analysis
    • 10.4.8. Russia Sales Analysis
    • 10.4.9. Rest Of Europe Sales Analysis
  • 10.5. Asia Pacific Sales Analysis
    • 10.5.1. Overview, Historic and Forecast Sales Analysis
    • 10.5.2. Asia Pacific by Segment Sales Analysis
    • 10.5.3. Asia Pacific by Country Sales Analysis
    • 10.5.4. China Sales Analysis
    • 10.5.5. India Sales Analysis
    • 10.5.6. Japan Sales Analysis
    • 10.5.7. South Korea Sales Analysis
    • 10.5.8. Australia Sales Analysis
    • 10.5.9. Rest Of Asia Pacific Sales Analysis
  • 10.6. Latin America Sales Analysis
    • 10.6.1. Overview, Historic and Forecast Sales Analysis
    • 10.6.2. Latin America by Segment Sales Analysis
    • 10.6.3. Latin America by Country Sales Analysis
    • 10.6.4. Brazil Sales Analysis
    • 10.6.5. Argentina Sales Analysis
    • 10.6.6. Peru Sales Analysis
    • 10.6.7. Chile Sales Analysis
    • 10.6.8. Rest of Latin America Sales Analysis
  • 10.7. Middle East & Africa Sales Analysis
    • 10.7.1. Overview, Historic and Forecast Sales Analysis
    • 10.7.2. Middle East & Africa by Segment Sales Analysis
    • 10.7.3. Middle East & Africa by Country Sales Analysis
    • 10.7.4. Saudi Arabia Sales Analysis
    • 10.7.5. UAE Sales Analysis
    • 10.7.6. Israel Sales Analysis
    • 10.7.7. South Africa Sales Analysis
    • 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE GENE VECTOR COMPANIES

  • 11.1. Gene Vector Market Competition
  • 11.2. Partnership/Collaboration/Agreement
  • 11.3. Merger And Acquisitions
  • 11.4. New Product Launch
  • 11.5. Other Developments

12 . COMPANY PROFILES OF GENE VECTOR INDUSTRY

  • 12.1. Top Company Share Analysis
  • 12.2. Market Concentration Rate
  • 12.3. Lonza
    • 12.3.1. Company Overview
    • 12.3.2. Company Revenue
    • 12.3.3. Products
    • 12.3.4. Recent Developments
  • 12.4. Merck KGaA
    • 12.4.1. Company Overview
    • 12.4.2. Company Revenue
    • 12.4.3. Products
    • 12.4.4. Recent Developments
  • 12.5. Oxford Biomedica
    • 12.5.1. Company Overview
    • 12.5.2. Company Revenue
    • 12.5.3. Products
    • 12.5.4. Recent Developments
  • 12.6. CGT Catapult
    • 12.6.1. Company Overview
    • 12.6.2. Company Revenue
    • 12.6.3. Products
    • 12.6.4. Recent Developments
  • 12.7. Charles River Laboratories
    • 12.7.1. Company Overview
    • 12.7.2. Company Revenue
    • 12.7.3. Products
    • 12.7.4. Recent Developments
  • 12.8. uniQure N.V.
    • 12.8.1. Company Overview
    • 12.8.2. Company Revenue
    • 12.8.3. Products
    • 12.8.4. Recent Developments
  • 12.9. FUJIFILM Diosynth Biotechnologies
    • 12.9.1. Company Overview
    • 12.9.2. Company Revenue
    • 12.9.3. Products
    • 12.9.4. Recent Developments
  • 12.10. Spark Therapeutics Inc.
    • 12.10.1. Company Overview
    • 12.10.2. Company Revenue
    • 12.10.3. Products
    • 12.10.4. Recent Developments

 *Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

  •  Market Snapshot
  •  Drivers : Impact Analysis
  •  Restraints : Impact Analysis
  •  List of Raw Material
  •  List of Raw Material Manufactures
  •  List of Potential Buyers
  •  Analysis by Vector Type (USD MN)
  •  Lentivirus Market Sales by Geography (USD MN)
  •  Adenovirus Market Sales by Geography (USD MN)
  •  Adeno-associated Virus (AAV) Market Sales by Geography (USD MN)
  •  Plasmid DNA Market Sales by Geography (USD MN)
  •  Others Market Sales by Geography (USD MN)
  •  Analysis Market by Application (USD MN)
  •  Gene Therapy Market Sales by Geography (USD MN)
  •  Vaccinology Market Sales by Geography (USD MN)
  •  Others Market Sales by Geography (USD MN)
  •  Analysis by Disease (USD MN)
  •  Genetic Disorder Market Sales by Geography (USD MN)
  •  Cancer Market Sales by Geography (USD MN)
  •  Infectious Disease Market Sales by Geography (USD MN)
  •  Others Market Sales by Geography (USD MN)
  •  Analysis by End-user (USD MN)
  •  Scientific Research Market Sales by Geography (USD MN)
  •  CRO Market Sales by Geography (USD MN)
  •  CDMO Market Sales by Geography (USD MN)
  •  Others (Pharmaceutical, Biotechnology Companies) Market Sales by Geography (USD MN)
  •  Global Gene Vector Market Sales by Geography (USD MN)
  •  North America Market Analysis (USD MN)
  •  United State Market Analysis (USD MN)
  •  Canada Market Analysis (USD MN)
  •  Mexico Market Analysis (USD MN)
  •  Europe Market Analysis (USD MN)
  •  Europe Market Estimate by Country (USD MN)
  •  United Kingdom Market Analysis (USD MN)
  •  France Market Analysis (USD MN)
  •  Germany Market Analysis (USD MN)
  •  Italy Market Analysis (USD MN)
  •  Russia Market Analysis (USD MN)
  •  Spain Market Analysis (USD MN)
  •  Rest of Europe Market Analysis (USD MN)
  •  Asia Pacific Market Analysis (USD MN)
  •  China Market Analysis (USD MN)
  •  Japan Market Analysis (USD MN)
  •  India Market Analysis (USD MN)
  •  South Korea Market Analysis (USD MN)
  •  Australia Market Analysis (USD MN)
  •  Rest of Asia Pacific Market Analysis (USD MN)
  •  Latin America Market Analysis (USD MN)
  •  Brazil Market Analysis (USD MN)
  •  Argentina Market Analysis (USD MN)
  •  Peru Market Analysis (USD MN)
  •  Chile Market Analysis (USD MN)
  •  Rest of Latin America Market Analysis (USD MN)
  •  Middle East & Africa Market Analysis (USD MN)
  •  Saudi Arabia Market Analysis (USD MN)
  •  UAE Market Analysis (USD MN)
  •  Israel Market Analysis (USD MN)
  •  South Africa Market Analysis (USD MN)
  •  Rest of Middle East and Africa Market Analysis (USD MN)
  •  Partnership/Collaboration/Agreement
  •  Mergers And Acquisition

LIST OF FIGURES

  •  Research Scope of Gene Vector Report
  •  Market Research Process
  •  Market Research Methodology
  •  Global Gene Vector Market Size, by Region (USD MN)
  •  Porters Five Forces Analysis
  •  Market Attractiveness Analysis by Vector Type
  •  Market Attractiveness Analysis by Application
  •  Market Attractiveness Analysis by Disease
  •  Market Attractiveness Analysis by End-user
  •  Market Attractiveness Analysis by Region
  •  Value Chain Analysis
  •  Global Market Analysis by Vector Type (USD MN)
  •  Lentivirus Market Sales by Geography (USD MN)
  •  Adenovirus Market Sales by Geography (USD MN)
  •  Adeno-associated Virus (AAV) Market Sales by Geography (USD MN)
  •  Plasmid DNA Market Sales by Geography (USD MN)
  •  Others Market Sales by Geography (USD MN)
  •  Global Market Analysis by Application (USD MN)
  •  Gene Therapy Market Sales by Geography (USD MN)
  •  Vaccinology Market Sales by Geography (USD MN)
  •  Others Market Sales by Geography (USD MN)
  •  Global Market Analysis by Disease (USD MN)
  •  Genetic Disorder Market Sales by Geography (USD MN)
  •  Cancer Market Sales by Geography (USD MN)
  •  Infectious Disease Market Sales by Geography (USD MN)
  •  Others Market Sales by Geography (USD MN)
  •  Global Market Analysis by End-user (USD MN)
  •  Scientific Research Market Sales by Geography (USD MN)
  •  CRO Market Sales by Geography (USD MN)
  •  CDMO Market Sales by Geography (USD MN)
  •  Others (Pharmaceutical, Biotechnology Companies) Market Sales by Geography (USD MN)
  •  Global Market by Revenue
  •  North America Market by Revenue
  •  Europe Market by Revenue
  •  Asia Pacific Market by Revenue
  •  Latin America Market by Revenue
  •  Middle East & Africa Market by Revenue
  •  Recent Development in Industry
  •  Top Company Share Analysis

 * Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.